{"protocolSection":{"identificationModule":{"nctId":"NCT00870870","orgStudyIdInfo":{"id":"13930"},"secondaryIdInfos":[{"id":"CP02-0860","type":"OTHER","domain":"CDER"},{"id":"CP13-0811","type":"OTHER","domain":"ImClone, LLC"},{"id":"I5A-IE-JAEF","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before","officialTitle":"Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2018-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-03"},"primaryCompletionDateStruct":{"date":"2012-04","type":"ACTUAL"},"completionDateStruct":{"date":"2012-05","type":"ACTUAL"},"studyFirstSubmitDate":"2009-03-26","studyFirstSubmitQcDate":"2009-03-26","studyFirstPostDateStruct":{"date":"2009-03-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-17","resultsFirstSubmitQcDate":"2018-05-01","resultsFirstPostDateStruct":{"date":"2018-06-01","type":"ACTUAL"},"dispFirstSubmitDate":"2010-09-03","dispFirstSubmitQcDate":"2010-09-03","dispFirstPostDateStruct":{"date":"2010-09-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-05-01","lastUpdatePostDateStruct":{"date":"2018-06-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.","detailedDescription":"Participants with Stage IIIb or IV non-small cell lung cancer (NSCLC) who have not received previous chemotherapy will be stratified, based on disease histology (squamous versus \\[vs.\\] nonsquamous)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Tumors","Antibodies, Monoclonal","Stage IIIb Metastatic Non-Small Cell Lung Cancer","Stage IV Metastatic Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":64,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)","type":"EXPERIMENTAL","description":"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met\n\n\\*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)","interventionNames":["Drug: Gemcitabine","Drug: Cisplatin","Biological: IMC-A12 (cixutumumab)","Biological: Cetuximab","Drug: Carboplatin"]},{"label":"GCiC (Gemcitabine/Cisplatin/Cetuximab)","type":"ACTIVE_COMPARATOR","description":"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met\n\n\\*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)","interventionNames":["Drug: Gemcitabine","Drug: Cisplatin","Biological: Cetuximab","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Gemcitabine","description":"1000 milligrams per square meter (mg/m\\^2) on Days 1 and 8 of each cycle\n\n\\[First 6 cycles (18 weeks)\\]","armGroupLabels":["GCiC (Gemcitabine/Cisplatin/Cetuximab)","GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m\\^2 on Day 1 of each cycle\n\n\\[First 6 cycles (18 weeks)\\]","armGroupLabels":["GCiC (Gemcitabine/Cisplatin/Cetuximab)","GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"]},{"type":"BIOLOGICAL","name":"IMC-A12 (cixutumumab)","description":"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)\n\n\\[First 6 cycles (18 weeks)\\]","armGroupLabels":["GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"],"otherNames":["Cixutumumab","LY3012217"]},{"type":"BIOLOGICAL","name":"Cetuximab","description":"400 mg/m\\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\\^2 once per week thereafter\n\n\\[First 6 cycles (18 weeks)\\]","armGroupLabels":["GCiC (Gemcitabine/Cisplatin/Cetuximab)","GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"],"otherNames":["Erbitux®"]},{"type":"BIOLOGICAL","name":"IMC-A12 (cixutumumab)","description":"10 mg/kg IV infusion, administered once every 2 weeks\n\n(Maintenance therapy)","armGroupLabels":["GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"],"otherNames":["Cixutumumab","LY3012217"]},{"type":"BIOLOGICAL","name":"Cetuximab","description":"500 mg/m\\^2 IV infusion, administered once every 2 weeks\n\n(Maintenance therapy)","armGroupLabels":["GCiC (Gemcitabine/Cisplatin/Cetuximab)","GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"],"otherNames":["Erbitux®"]},{"type":"DRUG","name":"Carboplatin","description":"Area under the curve (AUC) = 5, Day 1 of each cycle\n\n\\[First 6 cycles (18 weeks)\\]\n\n\\*Carboplatin will be replaced by Cisplatin","armGroupLabels":["GCiC (Gemcitabine/Cisplatin/Cetuximab)","GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]","description":"ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and the normalization of the tumour marker level. PR was defined as having at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Percentage of participants is calculated as a total number of participants with CR or PR / total number of participants treated \\* 100.","timeFrame":"Randomization to measured progressive disease (PD) (up to 16.9 months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.","timeFrame":"Randomization to death due to any cause or censor (up to 30.4 months)"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the duration from the date of randomization until disease progression or death due to any cause, whichever occurred first. Response was defined using RECIST, v 1.0 criteria. PD was defined as having a ≥20% increase in sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants who were alive and without disease progression, PFS was censored at the date of last objective tumor assessment. For participants who did not experience disease progression and were lost to follow-up, PFS was censored at the date of the last objective tumor assessment or the date of last contact.","timeFrame":"Randomization to PD or death due to any cause or censor (up to 16.9 months)"},{"measure":"Time To Progression (TTP)","description":"TTP was defined as the duration from the date of randomization until the date of disease progression. Response was defined using RECIST v 1.0 criteria. PD was defined as having a ≥20% increase in the sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants without disease progression, TTP was censored at the date of last objective tumor assessment. For participants without disease progression and were subsequently lost to follow-up, TTP was censored at the date of last follow-up visit or at the date of last contact.","timeFrame":"Randomization to months until PD or censor (up to 16.9 months)"},{"measure":"Duration of Response","description":"The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of disease progression or death. Response was defined using RECIST v 1.0 criteria. CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as having at least a 30% decrease in sum of LD of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of disease progression.","timeFrame":"Date of first response to the date of PD or death due to any cause or censor ( up to 15.5 months)"},{"measure":"Number of Participants With Adverse Events (AEs) or Deaths","description":"Data presented are the number of participants who experienced 1 or more AEs, serious AEs (SAEs), and AEs that lead to death during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.","timeFrame":"Randomization to last dose of study medication (up to 11.7 months) plus 30-day safety follow-up"},{"measure":"Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)","timeFrame":"Prior to first infusions of Cycles 1, 3, and 5 and 30 days following the end of therapy"},{"measure":"Maximum Concentration (Cmax) of Cixutumumab at Study Day 1","timeFrame":"Day 1"},{"measure":"Cmax of Cixutumumab for Cycle 1","timeFrame":"Week 1 (Cycle 1, Day 1)"},{"measure":"Cmax of Cixutumumab for Cycle 3","timeFrame":"Week 7 (Cycle 3, Day 1)"},{"measure":"Cmax of Cixutumumab Cycle 5","timeFrame":"Week 13 (Cycle 5, Day 1)"},{"measure":"Minimum Concentration (Cmin) of Cixutumumab at Study Day 1","timeFrame":"Day 1"},{"measure":"Cmin of Cixutumumab for Cycle 1","timeFrame":"Week 1 (Cycle 1, Day 1)"},{"measure":"Cmin of Cixutumumab for Cycle 3","timeFrame":"Week 7 (Cycle 3, Day 1)"},{"measure":"Cmin of Cixutumumab for Cycle 5","timeFrame":"Week 13 (Cycle 5, Day 1)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC\n* Has metastatic disease\n* Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST)\n* Has adequate hematologic function\n* Has adequate hepatic function\n* Has adequate renal function\n* Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\n\nExclusion Criteria:\n\n* Has uncontrolled brain metastases\n* Has leptomeningeal disease\n* Has received previous chemotherapy for NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)\n* Receiving any other investigational agent(s)\n* Has a history of treatment with other agents targeting the insulin-like growth factor (IGF) or the epidermal growth factor (EGF) receptor\n* Has a known allergy / history of hypersensitivity reaction to any of the treatment components\n* Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range \\[fasting glucose \\<160 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) and hemoglobin A1C≤ 7%\\] and that they are on a stable dietary or therapeutic regimen for this condition\n* Has an uncontrolled intercurrent illness\n* Pregnant or lactating\n* Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years\n* Has superior vena cava syndrome contraindicating hydration\n* Has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure\n* Has any National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy\n* Has significant third space fluid retention, requiring repeated drainage","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"E-mail: ClinicalTrials@ ImClone.com","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"ImClone Investigational Site","city":"Anniston","state":"Alabama","zip":"36207","country":"United States","geoPoint":{"lat":33.65983,"lon":-85.83163}},{"facility":"ImClone Investigational Site","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"ImClone Investigational Site","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"ImClone Investigational Site","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"ImClone Investigational Site","city":"Atlanta","state":"Georgia","zip":"30341","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"ImClone Investigational Site","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"ImClone Investigational Site","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"ImClone Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87131","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"ImClone Investigational Site","city":"New York","state":"New York","zip":"10011","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"ImClone Investigational Site","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"ImClone Investigational Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"ImClone Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45247","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Gemcitabine/Carboplatin/Cetuximab (GCC)","description":"Gemcitabine: 1000 milligrams per square meter (mg/m\\^2) on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 once every week (Q1W) of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 once every 2 weeks (Q2W) in the subsequent cycles (2-week cycles).\n\nCarboplatin: Area under the curve (AUC) = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"FG001","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1 and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 milligrams per kilogram (mg/kg) intravenous (IV) infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"FG002","title":"Gemcitabine/Cisplatin/Cetuximab (GCiC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1 and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"FG003","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1 and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"25"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Gemcitabine/Carboplatin/Cetuximab (GCC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"BG001","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"BG002","title":"Gemcitabine/Cisplatin/Cetuximab (GCiC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"BG003","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycle).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"64"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.50","lowerLimit":"65.00","upperLimit":"74.00"},{"groupId":"BG001","value":"54.50","lowerLimit":"49.00","upperLimit":"69.00"},{"groupId":"BG002","value":"64.00","lowerLimit":"45.00","upperLimit":"77.00"},{"groupId":"BG003","value":"60.00","lowerLimit":"41.00","upperLimit":"77.00"},{"groupId":"BG004","value":"62.00","lowerLimit":"41.00","upperLimit":"77.00"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"27"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"37"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"63"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"58"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"6"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"64"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"173.10","spread":"3.982"},{"groupId":"BG001","value":"176.78","spread":"8.935"},{"groupId":"BG002","value":"170.04","spread":"9.356"},{"groupId":"BG003","value":"167.79","spread":"10.537"},{"groupId":"BG004","value":"169.99","spread":"9.758"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74.93","spread":"13.814"},{"groupId":"BG001","value":"80.43","spread":"16.720"},{"groupId":"BG002","value":"76.30","spread":"13.908"},{"groupId":"BG003","value":"72.90","spread":"15.957"},{"groupId":"BG004","value":"75.27","spread":"14.815"}]}]}]},{"title":"Body Surface Area (BSA)","description":"BSA is the measured or calculated surface area of a human body based on body weight and height.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"square meters (m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.89","spread":"0.186"},{"groupId":"BG001","value":"1.98","spread":"0.223"},{"groupId":"BG002","value":"1.89","spread":"0.214"},{"groupId":"BG003","value":"1.84","spread":"0.246"},{"groupId":"BG004","value":"1.88","spread":"0.225"}]}]}]},{"title":"Eastern Cooperative Oncology Status Performance Status (ECOG PS) Score","description":"ECOG performance status was used to classify participants according to their functional impairment. Score 0 = fully active, able to carry on all pre-disease performance without restriction. Score 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"0 = Fully Active","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"18"}]},{"title":"1 = Ambulatory, Restricted Work Activity","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"46"}]}]}]},{"title":"Randomization Stratum","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"30"}]},{"title":"Nonsquamous","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"34"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]","description":"ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and the normalization of the tumour marker level. PR was defined as having at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Percentage of participants is calculated as a total number of participants with CR or PR / total number of participants treated \\* 100.","populationDescription":"All participants randomized to GCiC and GCiC Plus Cixutumumab arms. Efficacy data were not summarized for the original treatment arms (GCC and GCC Plus Cixutumumab) since such summaries were not considered relevant to the study objectives under the amended protocol.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to measured progressive disease (PD) (up to 16.9 months)","groups":[{"id":"OG000","title":"Gemcitabine/Cisplatin/Cetuximab (GCiC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"14.2","upperLimit":"47.9"},{"groupId":"OG001","value":"20.0","lowerLimit":"4.3","upperLimit":"35.7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.","populationDescription":"All participants randomized to GCiC and GCiC Plus Cixutumumab arms. Participants censored: GCiC = 6, GCiC Plus cixutumumab = 6. Efficacy data were not summarized for the original treatment arms (GCC and GCC Plus Cixutumumab) since such summaries were not considered relevant to the study objectives under the amended protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to death due to any cause or censor (up to 30.4 months)","groups":[{"id":"OG000","title":"GCiC","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"5.3","upperLimit":"14.8"},{"groupId":"OG001","value":"8.9","lowerLimit":"7.0","upperLimit":"13.2"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the duration from the date of randomization until disease progression or death due to any cause, whichever occurred first. Response was defined using RECIST, v 1.0 criteria. PD was defined as having a ≥20% increase in sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants who were alive and without disease progression, PFS was censored at the date of last objective tumor assessment. For participants who did not experience disease progression and were lost to follow-up, PFS was censored at the date of the last objective tumor assessment or the date of last contact.","populationDescription":"All participants randomized to GCiC and GCiC Plus Cixutumumab arms. Participants censored: GCiC = 2, GCiC Plus cixutumumab = 10. Efficacy data were not summarized for the original treatment arms (GCC and GCC Plus Cixutumumab) since such summaries were not considered relevant to the study objectives under the amended protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to PD or death due to any cause or censor (up to 16.9 months)","groups":[{"id":"OG000","title":"GCiC","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"2.9","upperLimit":"6.2"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.6","upperLimit":"7.0"}]}]}]},{"type":"SECONDARY","title":"Time To Progression (TTP)","description":"TTP was defined as the duration from the date of randomization until the date of disease progression. Response was defined using RECIST v 1.0 criteria. PD was defined as having a ≥20% increase in the sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants without disease progression, TTP was censored at the date of last objective tumor assessment. For participants without disease progression and were subsequently lost to follow-up, TTP was censored at the date of last follow-up visit or at the date of last contact.","populationDescription":"All participants (pts) randomized to GCiC and GCiC Plus Cixutumumab arms. Participants censored: GCiC = 9, GCiC Plus Cixutumumab = 12. Efficacy data were not summarized for the original treatment arms (GCC and GCC Plus Cixutumumab) since such summaries were not considered relevant to the study objectives under the amended protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to months until PD or censor (up to 16.9 months)","groups":[{"id":"OG000","title":"GCiC","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.9","upperLimit":"6.7"},{"groupId":"OG001","value":"5.7","lowerLimit":"2.7","upperLimit":"11.7"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of disease progression or death. Response was defined using RECIST v 1.0 criteria. CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as having at least a 30% decrease in sum of LD of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of disease progression.","populationDescription":"All pts randomized to GCiC and GCiC Plus Cixutumumab arms and who had CR or PR, except 1 pt in GCiC group eliminated d/t PR after starting additional treatment. Participants censored: GCiC = 0, GCiC Plus Cixutumumab = 1. Efficacy data were not summarized for the original treatment arms (GCC and GCC Plus Cixutumumab) due to the amended protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of first response to the date of PD or death due to any cause or censor ( up to 15.5 months)","groups":[{"id":"OG000","title":"GCiC","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"4.2","upperLimit":"5.3"},{"groupId":"OG001","value":"4.8","lowerLimit":"2.9","upperLimit":"15.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) or Deaths","description":"Data presented are the number of participants who experienced 1 or more AEs, serious AEs (SAEs), and AEs that lead to death during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Randomization to last dose of study medication (up to 11.7 months) plus 30-day safety follow-up","groups":[{"id":"OG000","title":"Gemcitabine/Carboplatin/Cetuximab (GCC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG002","title":"Gemcitabine/Cisplatin/Cetuximab (GCiC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG003","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"}]}],"classes":[{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"15"}]}]},{"title":"Deaths Due to AEs","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)","populationDescription":"Zero participants analyzed. Analysis was not performed due to lack of an appropriate validated assay.","reportingStatus":"POSTED","timeFrame":"Prior to first infusions of Cycles 1, 3, and 5 and 30 days following the end of therapy","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) of Cixutumumab at Study Day 1","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Day 1","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmax of Cixutumumab for Cycle 1","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 1 (Cycle 1, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmax of Cixutumumab for Cycle 3","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 7 (Cycle 3, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmax of Cixutumumab Cycle 5","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 13 (Cycle 5, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Minimum Concentration (Cmin) of Cixutumumab at Study Day 1","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Day 1","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmin of Cixutumumab for Cycle 1","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 1 (Cycle 1, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmin of Cixutumumab for Cycle 3","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 7 (Cycle 3, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cmin of Cixutumumab for Cycle 5","populationDescription":"Zero participants analyzed. No PK samples analyzed due to being expired prior to assay developed to analyze.","reportingStatus":"POSTED","timeFrame":"Week 13 (Cycle 5, Day 1)","groups":[{"id":"OG000","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."},{"id":"OG001","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycle).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg Q2W in the subsequent cycles (2-week cycle).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Gemcitabine/Carboplatin/Cetuximab (GCC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met.","seriousNumAffected":4,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4},{"id":"EG001","title":"GCC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCarboplatin: AUC = 5 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met.","seriousNumAffected":5,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG002","title":"Gemcitabine/Cisplatin/Cetuximab (GCiC)","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met.","seriousNumAffected":20,"seriousNumAtRisk":29,"otherNumAffected":29,"otherNumAtRisk":29},{"id":"EG003","title":"GCiC Plus Cixutumumab","description":"Gemcitabine: 1000 mg/m\\^2 on Days 1 and 8 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCisplatin: 75 mg/m\\^2 on Day 1 of each 3-week cycle for a total of 6 cycles (18 weeks).\n\nCetuximab: Initial dose of 400 mg/m\\^2 on Day 1 of Cycle 1, and subsequent doses of 250 mg/m\\^2 Q1W of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 500 mg/m\\^2 Q2W in the subsequent cycles (2-week cycles).\n\nCixutumumab: 6 mg/kg IV infusion Q1W on Days 1, 8, and 15 of each 3-week cycle for a total of 6 cycles (18 weeks). Later administered at 10 mg/kg IV Q2W in the subsequent cycles (2-week cycles).\n\nTreatment was continued until disease progression, unacceptable toxicity, withdrawal of consent or any other discontinuation criteria were met.","seriousNumAffected":15,"seriousNumAtRisk":25,"otherNumAffected":25,"otherNumAtRisk":25}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Intracardiac thrombus","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Pneumatosis intestinalis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Infusion related reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Gallbladder non-functioning","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Wound infection pseudomonas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Medication error","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":25}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":25}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Pericardial effusion malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":25}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":31,"numAffected":10,"numAtRisk":29},{"groupId":"EG003","numEvents":27,"numAffected":9,"numAtRisk":25}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":6},{"groupId":"EG002","numEvents":44,"numAffected":17,"numAtRisk":29},{"groupId":"EG003","numEvents":22,"numAffected":12,"numAtRisk":25}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":42,"numAffected":18,"numAtRisk":29},{"groupId":"EG003","numEvents":55,"numAffected":19,"numAtRisk":25}]},{"term":"Ear discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":9,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":25}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":25,"numAffected":17,"numAtRisk":29},{"groupId":"EG003","numEvents":26,"numAffected":17,"numAtRisk":25}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":20,"numAffected":13,"numAtRisk":29},{"groupId":"EG003","numEvents":22,"numAffected":9,"numAtRisk":25}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":3,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":35,"numAffected":15,"numAtRisk":29},{"groupId":"EG003","numEvents":28,"numAffected":15,"numAtRisk":25}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":25}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":25}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":18,"numAffected":11,"numAtRisk":29},{"groupId":"EG003","numEvents":21,"numAffected":15,"numAtRisk":25}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":29},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":25}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":25}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Catheter thrombosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":25}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":12,"numAffected":4,"numAtRisk":6},{"groupId":"EG002","numEvents":28,"numAffected":21,"numAtRisk":29},{"groupId":"EG003","numEvents":34,"numAffected":17,"numAtRisk":25}]},{"term":"Infusion related reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":9,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Incision site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":8,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":9,"numAffected":5,"numAtRisk":25}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Blood amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":16,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":6,"numAffected":2,"numAtRisk":25}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":29},{"groupId":"EG003","numEvents":10,"numAffected":9,"numAtRisk":25}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":5,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":16,"numAffected":10,"numAtRisk":29},{"groupId":"EG003","numEvents":14,"numAffected":10,"numAtRisk":25}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":11,"numAffected":6,"numAtRisk":29},{"groupId":"EG003","numEvents":21,"numAffected":7,"numAtRisk":25}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":25}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":14,"numAffected":6,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":49,"numAffected":14,"numAtRisk":29},{"groupId":"EG003","numEvents":22,"numAffected":9,"numAtRisk":25}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":25}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":25}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":25}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":14,"numAffected":8,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":29},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":25}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":29},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":25}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":25}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":14}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":4},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":25}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":25}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":4},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":29},{"groupId":"EG003","numEvents":20,"numAffected":15,"numAtRisk":25}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":25}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Paranasal sinus hypersecretion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":25}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":29},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":25}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":4},{"groupId":"EG001","numEvents":12,"numAffected":5,"numAtRisk":6},{"groupId":"EG002","numEvents":21,"numAffected":12,"numAtRisk":29},{"groupId":"EG003","numEvents":12,"numAffected":8,"numAtRisk":25}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":13,"numAffected":9,"numAtRisk":25}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":25,"numAffected":14,"numAtRisk":29},{"groupId":"EG003","numEvents":35,"numAffected":17,"numAtRisk":25}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":12,"numAffected":7,"numAtRisk":29},{"groupId":"EG003","numEvents":14,"numAffected":12,"numAtRisk":25}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":25}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":25}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":25}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection."},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"C557414","term":"cixutumumab"},{"id":"D000068818","term":"Cetuximab"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}